Argenica Therapeutics Limited (Argenica or the Company) announced that healthy participants in the first cohort of its Phase 1 clinical trial of ARG-007 have been successfully dosed, indicating good safety and tolerability of ARG-007 in these participants. All dosed subjects have shown no serious safety issues following dosing. Follow up data will be presented to the Scientific Review Committee (SRC) in the coming days to seek approval to progress to the second cohort.

Should the SRC approve Argenica to progress to dosing the second cohort, a sentinel dosing will be initiated immediately. The sentinel participant is a single volunteer who receives the investigational drug at least 24 hours prior to the remaining subjects in the dose cohort. A second volunteer receives a placebo injection of saline at the same time as the sentinel subject.

The intention of the sentinel is to identify any unpredicted serious safety issues related to drug dosing in a single subject prior to exposing a larger group of subjects.